Targeted protein degradation represents a promising therapeutic strategy to overcome cancer's evasion of immune surveillance and resistance to conventional treatments. Researchers led by Zhang, Wang, and colleagues published their findings in Frontiers in Immunology, examining how this approach can dismantle previously undruggable targets that enable tumor cells to escape therapeutic interventions. The study addresses a critical challenge in oncology: many proteins driving immune evasion and therapy resistance have proven resistant to traditional small-molecule inhibitors. By employing targeted protein degradation technologies, which selectively eliminate problematic proteins rather than merely inhibiting their function, the research demonstrates how this mechanism can restore anti-tumor immunity and sensitize resistant cancers to treatment. This work is significant because it expands the therapeutic toolkit beyond conventional drugging strategies, potentially transforming the treatment landscape for cancers that have developed resistance mechanisms. The findings suggest targeted protein degradation could unlock new treatment possibilities for previously intractable malignancies.

This article, published in Frontiers in Immunology by Li, Zhang, Wu, Huang, and Qi, examines advances in nanomaterial-based delivery systems designed to induce transplantation tolerance. The research addresses a critical challenge in organ transplantation: achieving immune tolerance to grafted organs while minimizing reliance on long-term immunosuppressive therapies. The authors explore how engineered nanomaterials can serve as sophisticated platforms for delivering immunomodulatory agents directly to target immune cells and tissues. By leveraging nanotechnology's precision and biocompatibility, these delivery systems offer enhanced control over immune regulation pathways. The key innovation lies in the ability to tailor nanomaterial properties to promote regulatory immune responses and suppress rejection mechanisms. This approach is particularly significant because it could reduce transplant recipients' dependence on systemic immunosuppression, thereby decreasing treatment-related complications and improving long-term graft survival. The synthesis of nanotechnology with transplant immunology represents a promising frontier for developing more effective, safer therapeutic interventions in organ transplantation.

Flavonoids, naturally occurring plant compounds with established antioxidant, anti-inflammatory, antiviral, and antibacterial properties, represent promising therapeutic agents for infectious diseases and pandemic-related health challenges. However, their clinical application has been severely limited by poor aqueous solubility, inadequate oral bioavailability, rapid metabolism, structural instability, and insufficient tissue targeting. Researchers from Qassim University conducted a comprehensive literature review of studies published between 2015 and 2025, examining nanotechnology-based approaches to overcome these limitations. The review, published in the International Journal of Nanomedicine, evaluates multiple delivery systems including polymeric nanoencapsulates, lipid nanoparticles, nanoemulsions, nanocrystals, liposomes, and solid lipid nanoparticles (SLNPs). These nanotechnology-enabled formulations significantly enhance flavonoid solubility, absorption, stability, and bioavailability while enabling controlled and sustained therapeutic release at target tissues. This advancement is clinically significant as it transforms flavonoids into viable pharmaceutical interventions, potentially expanding treatment options for infectious diseases and improving therapeutic efficacy in pandemic response scenarios.

Functionalized bio-polymer hydrogels represent a promising advancement in cancer therapy, addressing critical limitations of current treatments including poor tumor selectivity, significant side effects, and therapeutic inefficacy. Researchers at Zhejiang Provincial People's Hospital conducted a comprehensive review of recent developments in hydrogel-based drug delivery systems, examining polymer selection, cross-linking methodologies, ligand-directed tumor targeting, and responsiveness to tumor microenvironmental conditions. These multifunctional hydrogels enable precise temporal and spatial control over drug release, supporting diverse therapeutic modalities including chemotherapy, immunotherapy, gene therapy, and phototherapy. The review explores clinical applications of injectable, implantable, and three-dimensional bioprinted hydrogels. While substantial progress has been achieved, challenges surrounding reproducibility, scalability, and clinical translation remain. The authors propose future directions including artificial intelligence-assisted design, patient-customized delivery systems, and multi-responsive formulations to overcome these obstacles. Given the escalating global cancer burden projected to reach 34.4 million new cases annually by 2050, biocompatible, tailored hydrogels offer transformative potential for precision oncology and represent a disruptive approach to next-generation cancer treatment strategies.

Researchers have developed an innovative therapeutic approach for glioma treatment by engineering biomimetic nanoparticles functionalized with PD-1 and mesenchymal stem cell (MSC) membranes. Published in Frontiers in Immunology, this study by Li and colleagues addresses a critical challenge in brain tumor therapy: delivering drugs across the blood-brain barrier while simultaneously modulating immune response. The nanoparticles are loaded with elemene and cabazitaxel, chemotherapeutic agents designed to target glioma cells. The PD-1 functionalization enables immune checkpoint modulation, promoting anti-tumor immunity through immune remodeling. The MSC membrane coating provides biomimetic properties that enhance cellular compatibility and blood-brain barrier penetration, allowing therapeutic cargo to reach tumor sites more effectively. This dual-action strategy combines direct cytotoxic chemotherapy with immunotherapeutic benefits, addressing both efficacy and the immunosuppressive tumor microenvironment. The approach represents a significant advancement in brain tumor treatment, offering potential improvements in therapeutic outcomes for glioma patients who currently face limited treatment options due to drug delivery barriers and immune evasion mechanisms.

This open-access review, published in Molecular Biomedicine in August 2026, examines the immunological distinctions between "cold" and "hot" tumors and their implications for cancer treatment. Cold tumors, characterized by low immune infiltration and limited T-cell activity, represent a significant therapeutic challenge compared to immunologically active hot tumors. The article analyzes how dysregulation of the cancer-immunity cycle contributes to tumor immunosuppression and identifies key immunological determinants governing tumor phenotype. Critically, the review explores emerging nanotechnology-driven therapeutic approaches designed to convert cold tumors into immunologically responsive hot tumors. These advanced strategies aim to overcome intrinsic immunological barriers by enhancing immune cell infiltration, promoting antigen presentation, and reactivating anti-tumor immunity. By integrating immunological principles with nanomedicine innovations, these approaches offer promising avenues for improving immunotherapy efficacy in previously resistant malignancies, potentially expanding treatment options for patients with cold tumors who currently benefit minimally from conventional immunotherapeutic interventions.

Researchers have developed glutathione-functionalized selenium nanoparticles as a novel therapeutic approach, combining the antioxidant properties of selenium with the cellular protective capabilities of glutathione. This synthesis represents an advancement in nanomedicine, leveraging selenium's established biocompatibility and glutathione's role as a critical intracellular antioxidant molecule. The nanoparticles were characterized and evaluated for their potential biological applications, demonstrating enhanced cellular uptake and cytoprotective effects in experimental studies. The glutathione functionalization strategy improves the nanoparticles' stability and bioavailability while enabling targeted delivery mechanisms. These findings suggest significant potential for treating oxidative stress-related conditions, including neurodegenerative diseases, cancer, and inflammatory disorders. The work, published in Scientific Reports, contributes to the growing field of engineered nanomaterials for therapeutic intervention, offering a promising platform for future drug development and personalized medicine applications where oxidative damage plays a pathological role.

Metal-organic frameworks (MOFs), constructed through coordination-driven self-assembly of metal ions and organic linkers, represent a versatile class of porous nanomaterials with significant biomedical applications. This comprehensive review, published in the International Journal of Nanomedicine by Wang, Zhang, and colleagues from Shandong First Medical University, examines MOF-based and MOF-derived nanomaterials for cancer theranostics and antimicrobial interventions. The researchers systematically analyze synthetic strategies including pyrolysis, chemical etching, composite modification, and functional group introduction to create materials with tunable pore architecture and stimulus-responsive degradability. In oncology, MOFs function as multimodal imaging contrast agents and drug delivery carriers enabling combination therapies involving photodynamic, photothermal, chemodynamic, and immunomodulatory approaches. The review addresses critical clinical challenges including inadequate tumor-targeting selectivity, multidrug resistance, and immunosuppressive tumor microenvironments. Additionally, MOF-derived materials demonstrate antibacterial properties against antibiotic-resistant pathogens, offering potential solutions to escalating resistance concerns. By leveraging their adaptable metal nodes and high surface areas, these nanomaterials provide rational frameworks for overcoming limitations inherent in conventional nanocarrier platforms, advancing personalized precision medicine approaches.

Nanotechnology has revolutionized drug delivery through controlled release mechanisms and targeted accumulation, yet significant challenges remain in translating these innovations to clinical practice. This Research Topic addresses critical barriers to effective cancer therapeutics, including poor biodistribution, systemic toxicity, limited tumor penetration, and therapeutic resistance. Bioinspired and biomimetic delivery strategies offer promising solutions by leveraging natural cellular mechanisms. Key platforms include exosomes, extracellular vesicles, cell-membrane-derived systems, and biomimetic nanocarriers capable of delivering small molecules, nucleic acids, proteins, and immunomodulatory agents. These systems can navigate the complex tumor microenvironment, penetrate heterogeneous tumor tissue, and overcome immune evasion strategies. However, substantial hurdles remain in reproducible production, cargo loading, characterization, scale-up, regulatory approval, and demonstration of therapeutic efficacy in clinically relevant models. This collection emphasizes connecting carrier design innovations with resistance reversal, therapeutic outcomes, and manufacturing feasibility for solid tumors. Priority is placed on submissions addressing specific biological barriers or resistance mechanisms through exosome technology, cell membrane-coating approaches, and other biomimetic nanocarriers, while excluding generic nanoparticle synthesis and diagnostic-only applications, thereby advancing the field toward effective clinical translation.

Cancer treatment remains limited by systemic toxicity, poor tumor targeting, and drug resistance, necessitating innovative delivery approaches. Exosomes have emerged as promising natural nanocarriers due to their nanoscale size of 30-150 nanometers, high biocompatibility, low immunogenicity, and ability to cross biological barriers including the blood-brain barrier. This comprehensive review examined 32 peer-reviewed studies published between January 2015 and April 2026, following PRISMA guidelines, to assess advances in engineered exosomes for targeted anticancer drug delivery. Key findings demonstrate that surface-engineering strategies including PEGylation, RGD, and GE11 modifications significantly improve tumor specificity and circulation stability. Cargo-loading methods such as electroporation, sonication, incubation, and extrusion enable delivery of diverse therapeutics including doxorubicin, paclitaxel, siRNA, miRNA, natural compounds like celastrol and curcumin, and CRISPR/Cas9 components. Particular progress has been achieved in overcoming multidrug resistance and enabling blood-brain barrier penetration. However, substantial challenges persist, including low loading efficiency, batch-to-batch variability, and lack of standardized protocols. Emerging solutions such as microfluidics-based production, immunomodulatory engineering, and artificial intelligence-assisted ligand design show promise for facilitating clinical translation of this technology.

# Professional Summary Researchers Diwan, Behera, and Murab have published a comprehensive review examining smart hydrogel-based anticancer strategies for postoperative osteosarcoma management. This work, featured in Frontiers in Biomaterials Science, addresses a critical clinical challenge in treating bone cancer following surgical intervention. Smart hydrogels represent an innovative biomaterial platform that can respond dynamically to physiological stimuli, enabling controlled drug delivery and localized therapeutic effects at tumor sites. These sophisticated materials show significant promise for preventing cancer recurrence and managing complications during the postoperative period in osteosarcoma patients. By leveraging stimuli-responsive mechanisms, smart hydrogels can enhance therapeutic efficacy while minimizing systemic toxicity associated with conventional anticancer treatments. The research underscores the potential of advanced biomaterial engineering to revolutionize postoperative cancer care, particularly for aggressive bone malignancies. This emerging approach bridges surgical oncology with materials science, offering clinicians novel tools for improving patient outcomes and quality of life following osteosarcoma resection.

Synthetic biology represents a transformative discipline merging engineering principles with biological systems to address critical medical challenges. This comprehensive review, published in Molecular Biomedicine in August 2026, examines the expanding applications of synthetic biology across biomedicine. The article explores how engineered biological components and systems are being leveraged to develop novel therapeutics, diagnostic tools, and regenerative medicine approaches. Key applications discussed include the design of programmable cells, creation of biosensors for disease detection, and development of synthetic metabolic pathways for drug production. The review highlights how synthetic biology enables precise control over cellular behavior, offering unprecedented opportunities to treat genetic disorders, cancer, and infectious diseases. By systematically integrating biological design with clinical translation, synthetic biology promises to revolutionize healthcare delivery. This open-access review provides crucial insights for researchers, clinicians, and biotech professionals seeking to understand how engineered biological systems will shape the future of medicine and personalized therapeutics.

Drug delivery has evolved from simple molecular administration to sophisticated nanomedicine platforms that control solubility, circulation time, tissue distribution, and release timing. Modern drug delivery addresses critical biopharmaceutical challenges including poor aqueous solubility, enzymatic degradation, rapid clearance, and inability to cross biological barriers like the blood-brain barrier. This progression represents a shift from "exposure control" to "precision control," beginning with sustained-release formulations that provided smoother plasma concentrations, advancing to encapsulation technologies utilizing liposomes, lipid nanoparticles, and polymeric particles for site-specific delivery. Current-generation nanoplatforms integrate carrier design, surface functionalization, and stimuli-responsive mechanisms to release therapeutics precisely when and where needed, regulating release based on disease biology. Nanocarriers such as lipid-based and polymeric systems have become essential in enabling many potent yet poorly soluble, unstable, or rapidly excreted drugs to reach therapeutic concentrations at target sites. These advanced delivery systems significantly improve pharmacokinetics, biodistribution, safety profiles, and patient outcomes, converting biopharmaceutically challenged molecules into viable medicines.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality despite advances in resection, transplantation, and systemic treatments. Key limitations including tumor recurrence, drug resistance, toxicity, and tumor heterogeneity necessitate innovative therapeutic approaches. Researchers at Macau University of Science and Technology, led by Qian Ding and Yi Zhun Zhu, published a comprehensive review in Drug Design, Development and Therapy examining prodrug design strategies tailored to HCC's unique tumor microenvironment (TME). Prodrugs are pharmacologically inactive derivatives that convert to active drugs through chemical or enzymatic processes after administration. This analysis evaluates prodrugs activated by specific TME signals including acidity, redox imbalance, hypoxia, disease-associated enzymes, and lactate-coupled processes. The review distinguishes between true prodrugs and responsive carrier systems containing unmodified active drugs or imaging probes. By employing a clinically anchored framework, the study assesses whether proposed activation mechanisms effectively discriminate HCC from adjacent healthy, inflamed, fibrotic, or cirrhotic tissue, offering insights into personalized treatment strategies for improved therapeutic outcomes and reduced off-target toxicity.

# Professional Summary Researchers from China Medical University have published a comprehensive review examining the delivery of therapeutic agents to the tumor microenvironment, with particular focus on RNA interference-based cancer therapy. The study, led by Kefeng Wang and Dongyan Liu, explores small interfering RNA (siRNA) as a promising cancer treatment strategy. siRNA functions by recognizing and degrading complementary messenger RNAs in a sequence-specific manner, effectively silencing disease-causing genes at the post-transcriptional level. However, significant obstacles currently limit clinical application: siRNA exhibits poor physiological stability, rapid enzymatic degradation, inefficient cellular membrane penetration, and insufficient targeting specificity. This review synthesizes research progress on overcoming these delivery challenges through advanced nanomedicine approaches. Understanding effective delivery mechanisms for siRNA and other therapeutic molecules to tumor microenvironments is critical for advancing personalized cancer therapeutics and improving treatment efficacy while minimizing off-target effects. The work contributes essential insights for researchers developing next-generation RNA-based cancer interventions.

Cancer drug resistance remains a critical clinical challenge limiting durable treatment responses across oncology. This comprehensive review systematically examines resistance mechanisms across 22 cancer types, distinguishing between intrinsic resistance, where tumors fail initial treatment response, and acquired resistance emerging during or after therapy. Key molecular mechanisms identified include compensatory pathway activation, phenotypic plasticity, immune evasion, enhanced DNA damage repair, and survival of drug-tolerant persister cells. The analysis spans major therapeutic modalities including chemotherapy, targeted therapy, and immunotherapy, supported by clinical trial evidence. To address these challenges, the review presents emerging strategies such as rational drug combinations, microbiome modulation, adaptive and intermittent therapies, and advanced drug delivery systems. Additionally, cutting-edge research tools are transforming resistance investigation, including single-cell and spatial multiomic profiling, patient-derived tumor organoid and xenograft models, and artificial intelligence-powered predictive analytics. By integrating molecular, cellular, and clinical insights, this strategic framework advances understanding of cancer drug resistance mechanisms and provides actionable approaches for precision oncology development, ultimately improving long-term patient survival outcomes.

The immune microenvironment critically influences disease progression and therapeutic resistance across cancers, inflammatory conditions, and autoimmune disorders. Despite advances in immunotherapy and targeted treatments, their effectiveness remains limited by biological barriers, poor tissue penetration, and immune evasion. Addressing these challenges requires integrating artificial intelligence, multi-omics analysis, and advanced nanomedicine. Machine learning and bioinformatics identify novel biomarkers and therapeutic targets from large datasets, while AI-assisted radiomics and deep learning enable precise patient stratification and real-time treatment monitoring. Sophisticated nanocarrier systems—including lipid nanoparticles, stimulus-responsive polymers, and extracellular vehicles—deliver therapeutics and immunomodulators directly to disease microenvironments. This research initiative bridges computational science, clinical oncology and immunology, and materials science to establish a translational pipeline. It emphasizes using AI and bioinformatics to identify microenvironment vulnerabilities and deploying precision nanomedicines to target these weaknesses. Priority areas include AI-guided drug delivery using machine learning and single-cell sequencing, tumor microenvironment remodeling to overcome immunosuppression and checkpoint inhibitor resistance, and radiomics-based treatment evaluation through multimodal deep learning models.

Redox-modulating metallic nanoparticles represent an emerging frontier in cellular therapeutics, with researchers increasingly recognizing their potential to modulate oxidative stress pathways. This comprehensive review examines the mechanistic foundations underlying the pharmacological activity of these nanoparticles, published in Naunyn-Schmiedeberg's Archives of Pharmacology in August 2026. The article synthesizes current understanding of how metallic nanoparticles—including gold, silver, and iron oxide variants—interact with cellular redox systems to influence therapeutic outcomes. By elucidating the mechanisms through which these particles modulate reactive oxygen species production and antioxidant defenses, the review provides critical insights for therapeutic application development. The significance of this work lies in establishing evidence-based frameworks for leveraging redox modulation in treating diseases characterized by oxidative imbalance, including neurodegenerative conditions, cancer, and inflammatory disorders. Understanding these mechanistic pathways enables rational design of nanoparticle-based therapeutics with enhanced efficacy and reduced off-target effects, positioning redox-modulating metallic nanoparticles as promising candidates for next-generation pharmaceutical interventions.

Liposome-Exosome Hybrid Nanoparticles (LEHNs) represent an advanced biogenic delivery system that combines synthetic liposomes with naturally-derived exosomes to overcome current challenges in targeted drug and gene delivery. This hybrid approach leverages the high payload capacity and stability of liposomes with the inherent biocompatibility, low immunogenicity, and natural cell-targeting capabilities of exosomes. LEHNs enable efficient packaging and delivery of large therapeutic nucleic acids and gene manipulation tools into difficult-to-transfect cell types, while minimizing systemic toxicity and off-target effects. Key applications include tumor-targeted drug accumulation through engineering exosomal membrane proteins and therapeutic delivery to progenitor or immune cells for tissue repair and immune modulation. The technology demonstrates superior biomimetic specificity, enhanced payload capacity, reduced immunogenicity, and robust stability compared to conventional delivery systems. Success requires precise control over membrane fusion processes and careful optimization of liposome composition to maximize cargo loading while reducing cytotoxicity, making LEHNs a promising advancement for accelerating translational medicine projects and achieving superior cell-specific therapeutic delivery.

Despite decades of cancer vaccine research, therapeutic development has faced significant efficacy challenges, with Sipuleucel-T as the sole FDA-approved option until recently. However, personalized mRNA vaccines—specifically Moderna's mRNA-4157 and BioNTech's autogene cevumeran—have demonstrated substantial clinical promise, achieving notable reductions in recurrence risk and improved survival outcomes across multiple cancer types. These personalized vaccines harness patient-specific tumor neoantigens to generate targeted immune responses. The field encompasses diverse platforms including DNA-, mRNA-, peptide-, dendritic cell-, and whole-cell-based approaches, each confronting obstacles such as tumor heterogeneity and immunosuppressive microenvironments. Advanced delivery systems utilizing lipid-polymer hybrids, biomimetic membranes, and stimulus-responsive nanovaccines enhance lymph node targeting and dendritic cell activation. Integration with artificial intelligence for antigen selection and multiomics for patient stratification streamlines vaccine development, while combination strategies with checkpoint inhibitors strengthen durability. Clinical evidence increasingly supports efficacy in melanoma and pancreatic cancer, positioning personalized cancer vaccines as transformative precision immunotherapies that shift oncology from reactive treatment toward proactive, personalized cancer control.